Overall , breast cancer mortality was much the same between groups ( 26 % [ 15-43 ] for TARGIT vs 19 % [ 11-32 ] for EBRT ; p = 056 ) but there were significantly fewer non-breast-cancer deaths with TARGIT ( 14 % [ 08-25 ] vs 35 % [ 23-52 ] ; p = 00086 ) , attributable to fewer deaths from cardiovascular causes and other cancers .